Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
- Author(s)
- Tsuboi, M; Herbst, RS; John, T; Kato, T; Majem, M; Grohé, C; Wang, J; Goldman, JW; Lu, S; de Marinis, F; Shepherd, FA; Lee, KH; Le, NT; Dechaphunkul, A; Kowalski, D; Bonanno, L; Dómine, M; Poole, L; Bolanos, A; Rukazenkov, Y; Wu, YL;
- Details
- Publication Year 2024,Volume 19,Issue #2,Page 131-134
- Journal Title
- Targeted Oncology
- Publication Type
- Commentary
- Abstract
- This is a summary of the original article ‟Overall survival with osimertinib in resected EGFR-mutated NSCLC.ˮ Osimertinib blocks the activity of the epidermal growth factor receptor (EGFR) on cancer cells, causing cancer cell death and tumor shrinkage, and is an effective treatment for EGFR-mutated non-small cell lung cancer (NSCLC). The ADAURA study assessed the effects of osimertinib versus placebo in patients with EGFR-mutated (exon 19 deletion or L858R) early stage (IB-IIIA) NSCLC removed by surgery (resected). Previous results from ADAURA demonstrated that patients treated with osimertinib stayed alive and cancer-free (disease-free survival) significantly longer than patients who received placebo. Recent data showed the overall length of time patients were alive after starting treatment (overall survival). In both the primary stage II-IIIA and overall stage IB-IIIA populations, patients in the osimertinib group had a significant 51% reduction in the risk of death compared with the placebo group. The data demonstrated that osimertinib after surgery significantly improved overall survival in patients with resected, EGFR-mutated, stage IB-IIIA NSCLC.
- Publisher
- Springer Nature
- Department(s)
- Medical Oncology
- Publisher's Version
- https://doi.org/10.1007/s11523-024-01034-3
- Open Access at Publisher's Site
https://doi.org/10.1007/s11523-024-01034-3- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-05-07 04:32:39
Last Modified: 2024-05-07 04:39:44